학술논문
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Document Type
Article
Author
Source
In Blood Advances 26 September 2023 7(18):5272-5280
Subject
Language
ISSN
2473-9529